Nitrofurantoin (Macrobid) and Comprehensive Metabolic Panel (CMP) Monitoring

Liver Function Monitoring

• Routine liver‑function testing is not required for a short‑course (3–5 days) treatment of uncomplicated urinary‑tract infection, as the risk of hepatotoxicity is low in this setting. [2][3]4
• In patients with pre‑existing liver disease or when nitrofurantoin is used for prolonged therapy, enhanced laboratory and clinical monitoring (including repeat CMP) is advised to detect possible hepatic injury. 1

Renal Considerations and Drug Clearance

• Nitrofurantoin does not cause renal dysfunction directly, but reduced renal function impairs drug excretion and raises the risk of toxicity; therefore, renal function should be assessed before prescribing. 1
• Consensus guidance from the American Geriatrics Society recommends avoiding nitrofurantoin entirely in individuals whose creatinine clearance is < 30 mL/min. [5][6]7

Adverse‑Effect Frequency Not Reflected in CMP

• Gastro‑intestinal adverse effects (e.g., nausea, vomiting) occur in approximately 5–16 % of treated individuals, but these symptoms do not produce abnormal CMP results. 3